Could your genes help you understand your prostate cancer risk? Researchers are exploring genetic tests that could help you know when you may need screening or further tests.
In the BARCODE1 study, men with higher genetic risk had MRI and biopsy even when their PSA was not high. The results are promising, but more research is needed before this approach becomes routine.
What Is a Polygenic Risk Score?
A polygenic risk score (PRS) combines information from many common genetic variants to estimate your inherited risk of prostate cancer. It can show whether your risk is lower, average or higher than other people’s.
A higher score does not mean you will develop cancer. It may simply help you and your doctor decide whether you need more personalised screening.
Why Are Researchers Looking Beyond PSA Alone?
PSA testing can help assess your risk of prostate cancer, but PSA is not specific to cancer. Your PSA can rise for other reasons, while some important cancers may not cause a high PSA.
Your genetic risk could add another layer of information. In the future, it may help your doctor decide when you should start PSA testing, how often you need it or whether you may benefit from earlier MRI.
How Do Different Prostate Cancer Risk Tests Compare?
Genetic testing is only one part of prostate cancer risk assessment. Each test below answers a different question and may be used at a different stage of screening or diagnosis.
| Test or Factor | What It Tells You | Can It Diagnose Cancer? | Current Role |
| Polygenic risk score | Estimates inherited risk using many common genetic variants | No | Research/risk stratification; not routine UK screening |
| BRCA2 genetic testing | Identifies a pathogenic variant in a high-risk cancer-predisposition gene | No | Can identify men in the UK NSC targeted-screening group when age and family-history criteria are also met |
| PSA blood test | Measures PSA and helps assess prostate cancer risk | No | Established part of prostate cancer assessment and targeted screening |
| MRI | Shows suspicious areas in or around the prostate | No | Used to guide further diagnostic assessment |
| Biopsy | Examines prostate tissue microscopically | Yes, histologically | Used to confirm prostate cancer and determine grade |
| Family history/ancestry/age | Modify background risk | No | Important parts of clinical risk assessment |
No single test provides a complete answer. Future screening strategies are likely to combine several sources of information rather than rely on genetics alone.
What Was the BARCODE1 Study?
BARCODE1 explored whether your genes could help find prostate cancer earlier. Researchers used DNA from saliva samples from men aged 55–69 to calculate a polygenic risk score based on 130 genetic variants.
Men whose genetic risk was in the highest 10% were offered MRI and biopsy regardless of PSA level. This allowed researchers to test whether PRS could identify men who might benefit from further assessment.
Why Did BARCODE1 Use 130 Genetic Variants?
Your prostate cancer risk can be influenced by many genetic variants, rather than one single gene. BARCODE1 combined information from 130 variants to calculate an estimate of inherited prostate cancer risk.
The 130 variants are not a permanent genetic panel. The important point is that your combined genetic risk could help identify whether you may benefit from closer screening, such as MRI and biopsy.
Why Did Researchers Choose the Highest 10% of Genetic Risk?
BARCODE1 focused on men with the highest 10% of genetic risk because they were more likely to have prostate cancer. This allowed the study to focus MRI and biopsy on men with the highest inherited risk.
The 10% cut-off is not a permanent rule. In the future, your genetic risk may help your doctor decide how closely you need to be screened.
What Happened to the Men Taking Part in BARCODE1?
Men in the highest 10% of genetic risk were invited for MRI and biopsy regardless of their PSA result. Among those who completed both tests, prostate cancer was found in a substantial proportion.
This does not mean a high PRS gives you the same chance of having cancer. BARCODE1 deliberately selected a genetically higher-risk group, so its detection rate cannot be applied to an unselected population.
Evidence Note
BARCODE1 invited 40,292 men aged 55–69 to participate. A polygenic risk score was calculated for 6,393 men, and 745 were identified in the study’s highest-risk group. Among the 468 who completed MRI and biopsy, 187 prostate cancers were diagnosed.
This 40% detection rate should not be applied to an unselected person taking a commercial genetic test. BARCODE1 deliberately selected men at the upper end of polygenic risk before MRI and biopsy, so the study population was enriched for prostate cancer.
How Many Cancers Were Clinically Important?
Of the 187 cancers diagnosed, 103 were classified as intermediate risk or higher using the NCCN categories applied in BARCODE1. Forty were unfavourable intermediate, high or very high risk.
These categories were used for the research analysis and are not identical to the UK Cambridge Prognostic Group system. The finding does, however, show that PRS-based selection identified more than just low-grade cancer.
Why Was the BARCODE1 Finding About PSA So Interesting?
One important BARCODE1 finding was that some clinically relevant cancers were found in men who would not have met the PSA-and-MRI criteria used to model the existing UK diagnostic pathway.
This does not prove that genetic screening is better than PSA screening for everyone; further research is still needed.
Research Insight
BARCODE1 found that 103 of the 187 prostate cancers detected were classified as intermediate risk or higher, and 74 of these would not have met the PSA-and-MRI criteria used by the researchers to model the existing UK diagnostic pathway.
This is an important proof-of-concept finding because it suggests that inherited genetic risk could identify some clinically relevant cancers that conventional triggers might miss. However, BARCODE1 was not a randomised comparison of competing screening programmes, so larger prospective trials are still needed to determine whether PRS-based screening reduces advanced cancer or prostate-cancer mortality without creating excessive biopsies and overdiagnosis.
Where Does MRI Fit Into Genetic Screening?
BARCODE1 used your genetic risk to identify who should have further tests, not to replace MRI or biopsy. Men with higher genetic risk were offered MRI and biopsy to look for and confirm prostate cancer.
In the future, your genetic risk could help decide when you need PSA, MRI or both. Each test gives your doctor different information about your prostate cancer risk.
Could Genetic Risk Testing Find Cancer Earlier?
Potentially, yes. Your genetic risk is present long before cancer develops, so a high-risk result could help you start screening earlier rather than waiting for your PSA to rise.
In the future, your genetic risk could help your doctor decide when you need PSA, MRI or other tests. However, researchers still need to prove that earlier genetic screening can reduce prostate cancer deaths without causing unnecessary testing.
Did BARCODE1 Prove Genetic Screening Is Better Than PSA Screening?
No. BARCODE1 showed that if you have a high genetic risk, you may be more likely to have prostate cancer, including significant disease. But it did not prove that genetic screening is better than PSA testing.
You may eventually have your genetic risk used alongside PSA and MRI to personalise your screening. More research is needed to show whether this approach finds more aggressive cancers while reducing unnecessary tests and treatment.
Could Polygenic Screening Still Cause Overdiagnosis?
Yes. Even if your genetic risk is high, you may develop a slow-growing prostate cancer that would never have affected your health. Finding these cancers can lead to unnecessary tests, anxiety and treatment.
The aim of PRS screening should be to help find cancers that could seriously affect your health while avoiding unnecessary diagnosis and treatment. More research is needed to see whether it can achieve this balance.
Why Does Ancestry Matter in Genetic Risk Testing?
Your genetic risk score may not work equally well for everyone because many studies have mainly included people of European ancestry. If your ancestry is underrepresented, the score may be less accurate for you.
Researchers are working to make genetic screening more reliable for different populations. This is important if your genetic risk is going to guide when you need prostate cancer screening.
Is a Polygenic Risk Score the Same as BRCA2 Testing?
No. A BRCA2 test looks for a harmful change in one gene, while a PRS looks at many of your genetic variants to estimate your overall prostate cancer risk.
The UK NSC now recommends a targeted programme of PSA testing every two years for men aged 45–61 who have a pathogenic BRCA2 variant and relevant family history. PRS itself is not yet routinely used to guide prostate cancer screening.
UK Guidance Note
Following its March 2026 review, the UK National Screening Committee does not recommend population-wide prostate cancer screening. It does recommend a targeted screening programme using PSA every two years for men aged 45–61 who have both a pathogenic BRCA2 variant and a family history of breast, ovarian, pancreatic or prostate cancer.
The UK NSC does not currently recommend targeted screening for other risk groups, including PRS-defined groups, while further evidence is gathered. It is working with studies including TRANSFORM to determine whether screening can safely be extended to additional higher-risk populations in the future.
Could You Have a Genetic Risk Test Only Once?
Your underlying DNA sequence is generally stable throughout life, so a new biological sample may not always be needed. However, the polygenic risk score calculated from your genetic data can change as researchers discover additional risk variants and improve the statistical models used to calculate risk.
Your screening plan can also change as you get older, so any genetic result needs to be interpreted alongside your age, PSA results, family history and other clinical information.
Could PRS Be Combined With PSA, MRI and Family History?
Yes, your polygenic risk score could eventually be combined with other information to give a more personalised picture of your prostate cancer risk. Your doctor would still need to consider several factors rather than relying on genetics alone.
- Age and Family History: Your age and family history help your doctor understand your underlying prostate cancer risk.
- Genetic Risk: Your PRS may provide additional information about your inherited likelihood of developing prostate cancer.
- PSA Testing: Your PSA result can help identify whether further assessment may be appropriate for you.
- MRI Findings: An MRI can help your doctor investigate suspicious areas if your overall risk suggests that further testing is needed.
Combining these factors could eventually help determine when and how often you should be screened. However, PRS-guided screening is not yet routine UK practice and your genetic risk should not be considered on its own.
What Is the TRANSFORM Trial?
TRANSFORM is a major UK study looking at how your prostate cancer screening could improve. It is testing PSA, genetic risk testing and rapid MRI to see which approach could help you find important cancer earlier.
The aim is to identify screening approaches that detect clinically important cancers while limiting unnecessary tests and overdiagnosis. TRANSFORM may also help researchers understand how genetic testing could fit into your future screening.
What Still Needs to Be Proven Before PRS Screening Becomes Routine?
Researchers know that your polygenic risk score can be linked to your prostate cancer risk. What researchers still need to establish is whether PRS-guided screening reduces advanced prostate cancer or prostate-cancer mortality while limiting unnecessary tests, biopsies and overdiagnosis.
Your doctor would also need to know whether PRS screening is cost-effective and works accurately for different populations. You should also understand that a high score means higher risk, not a cancer diagnosis, while a low score does not mean you cannot develop prostate cancer.
What Does This Research Mean for You Today?
For now, you do not need to order a commercial polygenic risk test simply because you are worried about prostate cancer. Your risk assessment should still consider your age, family history, ancestry, PSA results and any known genetic variants.
If you are concerned about your risk, speak with your doctor about whether PSA testing or genetic counselling could be appropriate for you. Your genetic results should always be considered alongside your wider health information, rather than used on their own.
Myth vs Fact
| Myth | Fact |
| A high polygenic risk score means you have prostate cancer. | A PRS estimates inherited risk. It cannot diagnose prostate cancer. |
| A low PRS means you will not develop prostate cancer. | No genetic risk score eliminates risk. Age, family history and other factors still matter. |
| A PRS is the same as BRCA2 testing. | A PRS combines many common variants, while BRCA2 testing looks for a pathogenic variant in a specific high-risk gene. |
| BARCODE1 proved that PRS screening is better than PSA screening. | BARCODE1 produced promising results but was not a randomised head-to-head comparison of screening programmes. |
| A genetic risk test could replace PSA, MRI and biopsy. | Genetics may eventually help decide who needs other tests, but it does not replace tests used to assess or diagnose prostate cancer. |
| The UK now offers PRS screening routinely. | Current UK targeted screening is limited to a specific BRCA2 group. PRS-based screening remains under research. |
| Your genetic risk score can never change once tested. | Your DNA is stable, but the calculated PRS and its interpretation can change as genetic models improve. |
Key Takeaways
- A polygenic risk score combines many common genetic variants to estimate inherited prostate cancer risk; it does not diagnose cancer.
- BARCODE1 showed that selecting men with high polygenic risk can identify clinically relevant prostate cancers, including some that would not have met the study’s PSA-and-MRI criteria.
- BARCODE1 did not prove that PRS-based screening is superior to conventional screening or that it reduces prostate-cancer mortality.
- PRS performance can vary between ancestral populations, making diverse validation essential before widespread clinical use.
- The UK does not currently recommend population-wide or PRS-based prostate cancer screening.
- The UK NSC now recommends PSA screening every two years for men aged 45–61 who have a pathogenic BRCA2 variant together with the specified relevant family history.
- TRANSFORM is currently testing PSA, fast MRI and genetic-risk approaches to determine how future UK screening could be made safer and more personalised.
- Genetic risk testing should complement, not replace, assessment of symptoms, PSA abnormalities, MRI or biopsy when these are clinically indicated.
Frequently Asked Questions
1. What is a polygenic risk score for prostate cancer?
A polygenic risk score looks at many genetic variants to estimate your inherited risk of developing prostate cancer. A higher score means your risk may be higher than average, but it does not mean you have prostate cancer.
2. Can a genetic test predict whether you will develop prostate cancer?
No. A genetic risk test cannot tell you for certain whether you will develop prostate cancer. It estimates your inherited risk and could eventually help inform more personalised screening if PRS-guided approaches are validated for routine use.
3. Can genetic testing detect prostate cancer?
No. A polygenic risk score does not diagnose prostate cancer. It may identify men who could benefit from further tests such as PSA testing, MRI or biopsy.
4. What did the BARCODE1 study show?
BARCODE1 found that men with a high genetic risk of prostate cancer could have significant cancer detected through MRI and biopsy, including some cancers that may not have been identified through the PSA-based pathway studied. However, the study did not prove that genetic screening is better than PSA screening for everyone.
5. Is a high polygenic risk score the same as having prostate cancer?
No. A high polygenic risk score means you may have a higher inherited risk of prostate cancer. You would still need appropriate clinical assessment and, if indicated, tests such as PSA, MRI or biopsy to determine whether cancer is present.
6. Can you have a low genetic risk score and still develop prostate cancer?
Yes. A low polygenic risk score does not eliminate your risk of prostate cancer. Your age, family history, PSA, symptoms and other risk factors can still be important when deciding whether you need screening.
7. Could genetic testing reduce the need for PSA testing?
Not necessarily. Genetic testing is being studied as an additional tool rather than a replacement for PSA testing. In the future, your genetic risk may help your doctor decide when and how often you need PSA testing or MRI.
8. Does ancestry affect the accuracy of a polygenic risk score?
It can. Some genetic risk scores have been developed using data from populations that are predominantly of European ancestry. Researchers are working to improve their accuracy and usefulness across different ancestral backgrounds.
9. Is a polygenic risk score the same as BRCA2 genetic testing?
No. A polygenic risk score combines information from many genetic variants, while BRCA2 testing looks for specific harmful changes in the BRCA2 gene. Both can provide information about inherited cancer risk, but they are different types of genetic testing.
10. Should you have a genetic risk test for prostate cancer now?
You should not assume that you need a polygenic risk test simply because you are concerned about prostate cancer. Your doctor can consider your age, family history, ancestry, PSA and any known genetic risk factors before advising whether genetic counselling or testing could be appropriate for you.
Final Thoughts: Understanding Your Genetic Risk for Prostate Cancer
Genetic risk testing could eventually help make prostate cancer screening more personalised by identifying men who may benefit from earlier or closer monitoring. However, research is still developing, and your genetic risk should be considered alongside your age, family history, PSA results and other relevant factors rather than used on its own.
If you would like expert assessment for prostate symptoms, PSA changes or treatment options, you can contact our team at Prostate Clinic London to discuss your concerns and the next steps that may be appropriate for you.
References:
- UK National Screening Committee (UK NSC) (2026) Prostate cancer. Screening recommendation following the March 2026 review. Available at: https://view-health-screening-recommendations.service.gov.uk/prostate-cancer/
- McHugh, J.K., Bancroft, E.K., Saunders, E., Brook, M.N., McGrowder, E., Wakerell, S., James, D. et al. (2025) ‘Assessment of a polygenic risk score in screening for prostate cancer’, The New England Journal of Medicine, 392(14), pp. 1406–1417. doi: 10.1056/NEJMoa2407934. Available at: https://pubmed.ncbi.nlm.nih.gov/40214032/
- NHS (2024) PSA test. Last reviewed 2 September 2024. Available at: https://www.nhs.uk/tests-and-treatments/psa-test/
- Prostate Cancer UK (no date) TRANSFORM trial. Available at: https://prostatecanceruk.org/research/for-researchers/transform
- Kim, M.S., Naidoo, D., Hazra, U., Quiver, M.H., Chen, W.C., Simonti, C.N. et al. (2022) ‘Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa’, Genome Biology, 23, article 194. doi: 10.1186/s13059-022-02766-z. Available at: https://pubmed.ncbi.nlm.nih.gov/36100952/
- Page, E.C., Bancroft, E.K., Brook, M.N., Assel, M., Al Battat, M.H., Thomas, S. et al. (2019) ‘Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers’, European Urology, 76(6), pp. 831–842. doi: 10.1016/j.eururo.2019.08.019. Available at: https://pubmed.ncbi.nlm.nih.gov/31537406/